Terms: = Uterine cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5
383 results:
1. Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs.
Santoro A; Bragantini E; Castiglione F; Ganesan R; Matias-Guiu X; Frattini M; Gallotta V; Garcia P; Pattni Y; Tsiampali-Laprell J; Bisaro B; Barbareschi M; Zannoni GF;
Pathologica; 2024 Feb; 116(1):32-45. PubMed ID: 38482673
[TBL] [Abstract] [Full Text] [Related]
2. Mismatch repair gene
Zhou LZ; Xiao HQ; Chen J
Front Immunol; 2024; 15():1302797. PubMed ID: 38390329
[TBL] [Abstract] [Full Text] [Related]
3. Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
Khushman MM; Toboni MD; Xiu J; Manne U; Farrell A; Lou E; Shields AF; Philip PA; Salem ME; Abraham J; Spetzler D; Marshall J; Jayachandran P; Hall MJ; Lenz HJ; Sahin IH; Seeber A; Powell MA
Clin Cancer Res; 2024 May; 30(9):1906-1915. PubMed ID: 38350001
[TBL] [Abstract] [Full Text] [Related]
4. Rare germline mutation and MSH2-&msh6 + expression in a double primary carcinoma of colorectal carcinoma and endometrial carcinoma: a case report.
Zhang T; Huang X; Liu W; Ling X; Su Z; Huang M; Che S
Diagn Pathol; 2024 Jan; 19(1):25. PubMed ID: 38297350
[TBL] [Abstract] [Full Text] [Related]
5. Next-generation sequencing and immunohistochemistry approaches for microsatellite instability detection in endometrial cancer.
Ali AS; Alalem LS
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):237-242. PubMed ID: 38279425
[TBL] [Abstract] [Full Text] [Related]
6. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications.
Addante F; d'Amati A; Santoro A; Angelico G; Inzani F; Arciuolo D; Travaglino A; Raffone A; D'Alessandris N; Scaglione G; Valente M; Tinnirello G; Sfregola S; Padial Urtueta B; Piermattei A; Cianfrini F; Mulè A; Bragantini E; Zannoni GF
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256131
[TBL] [Abstract] [Full Text] [Related]
7. New Insights into Lynch Syndrome: A Narrative Review.
Ene CV; Bulai CTLA; Geavlete P; Popescu RI; Vacaroiu IA; Georgescu DE; Isaconi IV; Munteanu MDLA; Ene CD; Militaru A; Geavlete B; Multescu R
Chirurgia (Bucur); 2023 Dec; 118(6):584-595. PubMed ID: 38228591
[TBL] [Abstract] [Full Text] [Related]
8. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
[TBL] [Abstract] [Full Text] [Related]
9. MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome.
Helderman NC; Andini KD; van Leerdam ME; van Hest LP; Hoekman DR; Ahadova A; Bajwa-Ten Broeke SW; Bosse T; van der Logt EMJ; Imhann F; Kloor M; Langers AMJ; Smit VTHBM; Terlouw D; van Wezel T; Morreau H; Nielsen M
J Mol Diagn; 2024 Feb; 26(2):106-114. PubMed ID: 38061582
[TBL] [Abstract] [Full Text] [Related]
10. Metastasis of endometrial adenocarcinoma masquerading as a primary rectal cancer: A rare case report with literature review.
Li M; Zheng W
Medicine (Baltimore); 2023 Nov; 102(46):e36170. PubMed ID: 37986305
[TBL] [Abstract] [Full Text] [Related]
11. Divergent Malignant Melanocytic Differentiation in Ovarian Endometrioid Adenocarcinoma With Aberrant β-Catenin Expression: A Case Expanding the Histologic Spectrum of β-Catenin Activated Gynecologic Neoplasia.
Xu J; Weisman PS
Int J Gynecol Pathol; 2024 May; 43(3):302-307. PubMed ID: 37922945
[TBL] [Abstract] [Full Text] [Related]
12. Validation of Modaplex POLE mutation assay in endometrial carcinoma.
Dorca E; Velasco A; Varela M; Gatius S; Villatoro S; Fullana N; Cuevas D; Vaquero M; Birnbaum A; Neumann K; Matias-Guiu X
Virchows Arch; 2023 Dec; 483(6):787-794. PubMed ID: 37874375
[TBL] [Abstract] [Full Text] [Related]
13. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract] [Full Text] [Related]
14. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
15. Comparison of Methods for Testing Mismatch Repair Status in Endometrial cancer.
Mendiola M; Heredia-Soto V; Ruz-Caracuel I; Baillo A; Ramon-Patino JL; Escudero FJ; Miguel M; Pelaez-Garcia A; Hernandez A; Feliu J; Hardisson D; Redondo A
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833916
[TBL] [Abstract] [Full Text] [Related]
16. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
Riedinger CJ; Esnakula A; Haight PJ; Suarez AA; Chen W; Gillespie J; Villacres A; Chassen A; Cohn DE; Goodfellow PJ; Cosgrove CM
Cancer; 2024 Feb; 130(3):385-399. PubMed ID: 37751191
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer.
Kim MK; So KA; Chun YK; Kim YH; Lim KT; Lee KH; Kim TJ
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):724-728. PubMed ID: 37679002
[TBL] [Abstract] [Full Text] [Related]
20. A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer.
Wang C; Kuang W; Zeng J; Ren Y; Liu Q; Sun H; Feng M; Liang D
PeerJ; 2023; 11():e15920. PubMed ID: 37663290
[TBL] [Abstract] [Full Text] [Related]
[Next]
